100.99 USD
+0.01 (+0.01%)
100.99 USD
0 (0%)
Taking everything into account, AMED scores 5 out of 10 in our fundamental rating. AMED was compared to 100 industry peers in the Health Care Providers & Services industry. While AMED has a great profitability rating, there are some minor concerns on its financial health. AMED has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year AMED was profitable.
AMED had a positive operating cash flow in the past year.
Of the past 5 years AMED 4 years were profitable.
Each year in the past 5 years AMED had a positive operating cash flow.
1.2 Ratios
The Return On Assets of AMED (3.87%) is better than 72.12% of its industry peers.
With a decent Return On Equity value of 6.95%, AMED is doing good in the industry, outperforming 66.35% of the companies in the same industry.
With an excellent Return On Invested Capital value of 10.34%, AMED belongs to the best of the industry, outperforming 81.73% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for AMED is in line with the industry average of 9.42%.
The 3 year average ROIC (9.73%) for AMED is below the current ROIC(10.34%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.87% | ||
| ROE | 6.95% | ||
| ROIC | 10.34% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
1.3 Margins
AMED has a better Profit Margin (3.56%) than 68.27% of its industry peers.
In the last couple of years the Profit Margin of AMED has declined.
With a decent Operating Margin value of 9.41%, AMED is doing good in the industry, outperforming 78.85% of the companies in the same industry.
In the last couple of years the Operating Margin of AMED has remained more or less at the same level.
AMED's Gross Margin of 43.19% is fine compared to the rest of the industry. AMED outperforms 71.15% of its industry peers.
In the last couple of years the Gross Margin of AMED has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.41% | ||
| PM (TTM) | 3.56% | ||
| GM | 43.19% |
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
2. Health
2.1 Basic Checks
AMED has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for AMED has been increased compared to 1 year ago.
The number of shares outstanding for AMED has been increased compared to 5 years ago.
The debt/assets ratio for AMED has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.10 indicates that AMED is not in any danger for bankruptcy at the moment.
AMED has a better Altman-Z score (4.10) than 75.00% of its industry peers.
The Debt to FCF ratio of AMED is 1.55, which is an excellent value as it means it would take AMED, only 1.55 years of fcf income to pay off all of its debts.
AMED's Debt to FCF ratio of 1.55 is amongst the best of the industry. AMED outperforms 85.58% of its industry peers.
AMED has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
AMED has a better Debt to Equity ratio (0.26) than 65.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.55 | ||
| Altman-Z | 4.1 |
ROIC/WACC1.2
WACC8.61%
2.3 Liquidity
AMED has a Current Ratio of 1.36. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
AMED's Current ratio of 1.36 is in line compared to the rest of the industry. AMED outperforms 44.23% of its industry peers.
AMED has a Quick Ratio of 1.36. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.36, AMED perfoms like the industry average, outperforming 50.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.36 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 11.24% over the past year.
The Earnings Per Share has been decreasing by -0.46% on average over the past years.
AMED shows a small growth in Revenue. In the last year, the Revenue has grown by 4.93%.
Measured over the past years, AMED shows a small growth in Revenue. The Revenue has been growing by 3.73% on average per year.
EPS 1Y (TTM)11.24%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%16.67%
Revenue 1Y (TTM)4.93%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%5.19%
3.2 Future
The Earnings Per Share is expected to grow by 6.47% on average over the next years.
Based on estimates for the next years, AMED will show a small growth in Revenue. The Revenue will grow by 4.95% on average per year.
EPS Next Y13.17%
EPS Next 2Y10.6%
EPS Next 3Y6.47%
EPS Next 5YN/A
Revenue Next Year4.17%
Revenue Next 2Y4.73%
Revenue Next 3Y4.95%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
AMED is valuated rather expensively with a Price/Earnings ratio of 21.26.
Based on the Price/Earnings ratio, AMED is valued a bit cheaper than the industry average as 67.31% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.34, AMED is valued at the same level.
The Price/Forward Earnings ratio is 19.15, which indicates a rather expensive current valuation of AMED.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AMED indicates a somewhat cheap valuation: AMED is cheaper than 62.50% of the companies listed in the same industry.
AMED is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.56, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.26 | ||
| Fwd PE | 19.15 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AMED is valued a bit cheaper than the industry average as 65.38% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of AMED indicates a somewhat cheap valuation: AMED is cheaper than 78.85% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.18 | ||
| EV/EBITDA | 11.63 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of AMED may justify a higher PE ratio.
PEG (NY)1.61
PEG (5Y)N/A
EPS Next 2Y10.6%
EPS Next 3Y6.47%
5. Dividend
5.1 Amount
No dividends for AMED!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
100.99
+0.01 (+0.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.54%
Inst Owner Change-95.61%
Ins Owners1.88%
Ins Owner Change-35.9%
Market Cap3.32B
Revenue(TTM)2.40B
Net Income(TTM)85.63M
Analysts54.12
Price Target102.87 (1.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.78%
Min EPS beat(2)12.12%
Max EPS beat(2)13.43%
EPS beat(4)2
Avg EPS beat(4)-0.15%
Min EPS beat(4)-15.99%
Max EPS beat(4)13.43%
EPS beat(8)3
Avg EPS beat(8)-1.75%
EPS beat(12)6
Avg EPS beat(12)2.15%
EPS beat(16)9
Avg EPS beat(16)3.64%
Revenue beat(2)1
Avg Revenue beat(2)-1.09%
Min Revenue beat(2)-2.2%
Max Revenue beat(2)0.01%
Revenue beat(4)1
Avg Revenue beat(4)-1.56%
Min Revenue beat(4)-2.2%
Max Revenue beat(4)0.01%
Revenue beat(8)2
Avg Revenue beat(8)-1.41%
Revenue beat(12)2
Avg Revenue beat(12)-2.17%
Revenue beat(16)2
Avg Revenue beat(16)-2.65%
PT rev (1m)0%
PT rev (3m)0.02%
EPS NQ rev (1m)7.75%
EPS NQ rev (3m)3.52%
EPS NY rev (1m)0%
EPS NY rev (3m)0.36%
Revenue NQ rev (1m)0.63%
Revenue NQ rev (3m)-0.23%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.26 | ||
| Fwd PE | 19.15 | ||
| P/S | 1.38 | ||
| P/FCF | 14.18 | ||
| P/OCF | 13.87 | ||
| P/B | 2.69 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.63 |
EPS(TTM)4.75
EY4.7%
EPS(NY)5.27
Fwd EY5.22%
FCF(TTM)7.12
FCFY7.05%
OCF(TTM)7.28
OCFY7.21%
SpS73.04
BVpS37.47
TBVpS-1.84
PEG (NY)1.61
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.87% | ||
| ROE | 6.95% | ||
| ROCE | 13.09% | ||
| ROIC | 10.34% | ||
| ROICexc | 12.85% | ||
| ROICexgc | 184.87% | ||
| OM | 9.41% | ||
| PM (TTM) | 3.56% | ||
| GM | 43.19% | ||
| FCFM | 9.75% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
ROICexc(3y)10.87%
ROICexc(5y)12.42%
ROICexgc(3y)283.58%
ROICexgc(5y)337.19%
ROCE(3y)12.32%
ROCE(5y)14.48%
ROICexgc growth 3Y57.65%
ROICexgc growth 5Y52.31%
ROICexc growth 3Y-5.72%
ROICexc growth 5Y-4.31%
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
F-Score6
Asset Turnover1.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.55 | ||
| Debt/EBITDA | 1.13 | ||
| Cap/Depr | 8.5% | ||
| Cap/Sales | 0.22% | ||
| Interest Coverage | 8.42 | ||
| Cash Conversion | 83.2% | ||
| Profit Quality | 273.49% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.36 | ||
| Altman-Z | 4.1 |
F-Score6
WACC8.61%
ROIC/WACC1.2
Cap/Depr(3y)21.03%
Cap/Depr(5y)20.63%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.24%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%16.67%
EPS Next Y13.17%
EPS Next 2Y10.6%
EPS Next 3Y6.47%
EPS Next 5YN/A
Revenue 1Y (TTM)4.93%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%5.19%
Revenue Next Year4.17%
Revenue Next 2Y4.73%
Revenue Next 3Y4.95%
Revenue Next 5YN/A
EBIT growth 1Y8.08%
EBIT growth 3Y-8.39%
EBIT growth 5Y3.2%
EBIT Next Year19.91%
EBIT Next 3Y9.46%
EBIT Next 5YN/A
FCF growth 1Y132.55%
FCF growth 3Y5.56%
FCF growth 5Y2%
OCF growth 1Y110.02%
OCF growth 3Y5.48%
OCF growth 5Y1.88%
AMEDISYS INC / AMED FAQ
Can you provide the ChartMill fundamental rating for AMEDISYS INC?
ChartMill assigns a fundamental rating of 5 / 10 to AMED.
What is the valuation status for AMED stock?
ChartMill assigns a valuation rating of 5 / 10 to AMEDISYS INC (AMED). This can be considered as Fairly Valued.
Can you provide the profitability details for AMEDISYS INC?
AMEDISYS INC (AMED) has a profitability rating of 7 / 10.
What are the PE and PB ratios of AMEDISYS INC (AMED) stock?
The Price/Earnings (PE) ratio for AMEDISYS INC (AMED) is 21.26 and the Price/Book (PB) ratio is 2.69.
Can you provide the expected EPS growth for AMED stock?
The Earnings per Share (EPS) of AMEDISYS INC (AMED) is expected to grow by 13.17% in the next year.